{"title":"Bibliometric analysis reveals global thymoma research trends collaborations and emerging frontiers from 2010 to 2024.","authors":"Zhen Yu, Yu-Han Li, Qi Han, Xin-Peng Wang, Xin-Tao Yu, Jian Cui, Xiang Gao, Xing-Guo Yang, Lei Yu","doi":"10.1007/s12672-025-03732-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To map global thymoma research trends (2010-2024) through bibliometric analysis.</p><p><strong>Methods: </strong>Analysis of 2,078 publications from Web of Science/PubMed using Bibliometrix, VOSviewer, and CiteSpace. Metrics included productivity (countries/institutions/authors), thematic evolution, collaboration networks, and citation impact.</p><p><strong>Results: </strong>The analysis reveals a steady increase (6.2% CAGR) in the volume of thymoma-related publications over the past decade. Key journals included Journal of Thoracic Oncology and Annals of Thoracic Surgery. Prolific authors like Marx Alexander (25 publications) and institutions such as Fudan University (67 publications) dominated the field. Keyword analysis revealed sustained focus on \"myasthenia gravis,\" \"surgery,\" and \"thymectomy,\" with emerging interest in \"immunotherapy\" and \"molecular biology.\" High-impact articles addressed autoimmune associations and novel therapies (e.g., sunitinib). Global collaboration networks highlighted strong partnerships among the U.S., Europe, and Asia, though logistical and policy barriers may have limited China's broader international engagement.</p><p><strong>Conclusion: </strong>Thymoma research has evolved toward molecular and therapeutic innovation, emphasizing immunotherapy and precision medicine. Despite growth, geographical disparities and understudied areas (e.g., long-term outcomes) persist. Future efforts should prioritize multidisciplinary collaboration, biomarker discovery, and multicenter trials to optimize clinical strategies.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1867"},"PeriodicalIF":2.9000,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12521727/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Discover. Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12672-025-03732-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To map global thymoma research trends (2010-2024) through bibliometric analysis.
Methods: Analysis of 2,078 publications from Web of Science/PubMed using Bibliometrix, VOSviewer, and CiteSpace. Metrics included productivity (countries/institutions/authors), thematic evolution, collaboration networks, and citation impact.
Results: The analysis reveals a steady increase (6.2% CAGR) in the volume of thymoma-related publications over the past decade. Key journals included Journal of Thoracic Oncology and Annals of Thoracic Surgery. Prolific authors like Marx Alexander (25 publications) and institutions such as Fudan University (67 publications) dominated the field. Keyword analysis revealed sustained focus on "myasthenia gravis," "surgery," and "thymectomy," with emerging interest in "immunotherapy" and "molecular biology." High-impact articles addressed autoimmune associations and novel therapies (e.g., sunitinib). Global collaboration networks highlighted strong partnerships among the U.S., Europe, and Asia, though logistical and policy barriers may have limited China's broader international engagement.
Conclusion: Thymoma research has evolved toward molecular and therapeutic innovation, emphasizing immunotherapy and precision medicine. Despite growth, geographical disparities and understudied areas (e.g., long-term outcomes) persist. Future efforts should prioritize multidisciplinary collaboration, biomarker discovery, and multicenter trials to optimize clinical strategies.
目的:通过文献计量学分析,绘制2010-2024年全球胸腺瘤研究趋势。方法:使用Bibliometrix、VOSviewer和CiteSpace对Web of Science/PubMed的2078篇出版物进行分析。指标包括生产力(国家/机构/作者)、主题演变、合作网络和引用影响。结果:分析显示,在过去十年中,胸腺瘤相关出版物的数量稳步增长(年复合增长率为6.2%)。重点期刊包括《胸外科肿瘤学杂志》、《胸外科年鉴》。马克思·亚历山大(25篇论文)等多产作者和复旦大学(67篇论文)等机构主导了这一领域。关键词分析显示,人们持续关注“重症肌无力”、“手术”和“胸腺切除术”,同时对“免疫疗法”和“分子生物学”也越来越感兴趣。高影响力的文章涉及自身免疫关联和新疗法(如舒尼替尼)。全球合作网络强调了美国、欧洲和亚洲之间强有力的伙伴关系,尽管后勤和政策障碍可能限制了中国更广泛的国际参与。结论:胸腺瘤研究已向分子和治疗创新方向发展,强调免疫治疗和精准医学。尽管有所增长,但地域差异和研究不足的领域(如长期结果)仍然存在。未来的努力应优先考虑多学科合作、生物标志物发现和多中心试验,以优化临床策略。